• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals

  • Print
  • Share
  • E-mail
Generic Name: bispecific T cell engager antibody construct with a half-life extension Fc moiety capable of binding to the neonatal Fc receptor
Date Designated: 09/11/2019
Orphan Designation: Treatment of Acute Myeloid Leukemia
Orphan Designation Status: Designated
FDA Orphan Approval Status: Not FDA Approved for Orphan Indication
Amgen Inc.
One Amgen Center Drive
Mail Stop 17-1-A
Thousand Oaks, California 91320
United States

The sponsor address listed is the last reported by the sponsor to OOPD.

*Exclusivity Protected Indications are shown for approvals from 01/01/2013 to the present.
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.